Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

dulanermin

A recombinant human soluble protein corresponding to amino acids 114-281 of the Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (RhApo2L/TRAIL) with potential antineoplastic activity. Dulanermin binds to and activates TRAIL receptors 1 and 2 (TRAIL-R1/R2), which may activate caspases and induce p53-independent apoptosis in TRAIL-R1/R2-expressing tumor cells. The pro-apoptotic cell surface receptors TRAIL-R1 and -R2, also known as DR4 (death receptor 4) and DR5 (death receptor 5), are members of the TNF receptor family and are overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:recombinant human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
recombinant TNF-related apoptosis-inducing ligand
Abbreviation:RhApo2L/TRAIL
Code name:AMG 951
Chemical structure:114-281-protein TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) (synthetic human)
human tumor necrosis factor ligand superfamily member 10 (TNF-related apoptosis- inducing ligand or Apo-2 ligand or CD253 antigen)-(114-281)-peptide (C-terminal part of the extracellular domain), noncovalent homotrimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search